- Home
- PII vs HCM Comparison
PII vs HCM Comparison
Compare PII & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PII
- HCM
- Stock Information
- Founded
- PII 1954
- HCM 2000
- Country
- PII United States
- HCM Hong Kong
- Employees
- PII N/A
- HCM N/A
- Industry
- PII Recreational Games/Products/Toys
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- PII Consumer Discretionary
- HCM Health Care
- Exchange
- PII Nasdaq
- HCM Nasdaq
- Market Cap
- PII 2.6B
- HCM 2.6B
- IPO Year
- PII 1987
- HCM N/A
- Fundamental
- Price
- PII $57.32
- HCM $17.93
- Analyst Decision
- PII Hold
- HCM
- Analyst Count
- PII 11
- HCM 0
- Target Price
- PII $45.30
- HCM N/A
- AVG Volume (30 Days)
- PII 1.2M
- HCM 55.8K
- Earning Date
- PII 10-21-2025
- HCM 08-07-2025
- Dividend Yield
- PII 4.68%
- HCM N/A
- EPS Growth
- PII N/A
- HCM N/A
- EPS
- PII N/A
- HCM 0.53
- Revenue
- PII $6,961,400,000.00
- HCM $602,197,000.00
- Revenue This Year
- PII N/A
- HCM $2.73
- Revenue Next Year
- PII $4.22
- HCM $17.33
- P/E Ratio
- PII N/A
- HCM $6.48
- Revenue Growth
- PII N/A
- HCM N/A
- 52 Week Low
- PII $30.92
- HCM $11.51
- 52 Week High
- PII $86.51
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- PII 53.31
- HCM 65.46
- Support Level
- PII $57.28
- HCM $15.51
- Resistance Level
- PII $60.57
- HCM $16.28
- Average True Range (ATR)
- PII 1.88
- HCM 0.33
- MACD
- PII -0.17
- HCM 0.24
- Stochastic Oscillator
- PII 46.37
- HCM 90.00
About PII Polaris Inc.
Polaris designs and manufactures off-road vehicles, including all-terrain vehicles and side-by-side vehicles for recreational and utility purposes, snowmobiles, and on-road vehicles, including motorcycles, along with the related replacement parts, garments, and accessories. The firm entered the marine market after acquiring Boat Holdings in 2018, offering exposure to another segment of the outdoor lifestyle market. Polaris products are retailed through more than 2,500 dealers in North America and 1,500 international dealers as well as more than 25 subsidiaries and 90 distributors in more than 100 countries outside North America.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.